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Abstract
The aim of this study was to assess the feasibility of cell-free DNA extraction and circulating tumor DNA
sequencing in 30-year-old serum samples of patients with breast cancer. Cell-free DNA extraction was suc-
cessful in 52 of 52 patients, and 24 cancer-specific mutations were found in 22 of 25 samples undergoing
sequencing. This study shows that next-generation sequencing technology is sufficiently robust and specific to
analyze 30-year-old serum.
Introduction: The aim of this study was to assess the feasibility of cell-free DNA (cfDNA) extraction and circulating
tumor DNA sequencing in 30-year-old serum samples.Materials and Methods:We evaluated serum samples from 52
patients with breast cancer, which were collected between 1983 and 1991, with correlating clinicopathologic data.
cfDNA was extracted by using the QIAamp Circulating Nucleic Acid Extraction Kit (Qiagen). Of these 52 cfDNA
samples, 10 were randomly selected and sequenced with the Oncomine Breast cfDNA Assay (A31183). In a second
step, high-depth targeted sequencing of 15 additional cfDNA samples was performed using a custom Ampliseq Ion
Torrent panel targeting breast cancer-related genes. Results: cfDNA extraction was successful in 52 (100%) of 52
patients with a total concentration of 0.2 to 54 ng/uL. A total of 24 cancer-specific mutations were found in 22 (88%) of
the 25 samples undergoing sequencing. Of the 52 patients, 32 (62%) had died from breast cancer after a median
follow-up of 7.9 years (interquartile range, 3.7-15.5 years). Conclusion: The present study shows that current next
generation sequencing technology is sufficiently robust and specific to analyze 30-year-old serum. Therefore,
longitudinal studies can be designed with storage of serum samples over many years, thereby obviating the need for
timely and continuous cfDNA extraction and sequencing. The samples can be pooled and processed at once with the
most modern technology available at the end of the study, when accumulation of events allows correlation of clinical
outcomes with adequate power.
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Mutation Identification in 30-year-old SerumIntroduction
A breakthrough in next-generation sequencing (NGS) in the past
decade provided an unprecedented opportunity to investigate
genetic variations in humans and their roles in health and disease. In
particular, large-scale efforts such as The Cancer Genome Atlas and
the International Cancer Genome Consortium have provided a
comprehensive molecular portrait of human cancers.1,2 The
discovery of the so-called ‘driver genes’ has provided the basis for the
development of the concept of precision medicine, where the
identification of targetable alterations guides the therapeutic
approach in treating patients with cancer. Nowadays, the decreasing
costs of massively parallel sequencing have resulted in increased
adoption of genomic profiling as part of the standard diagnostic
procedures in most tumor types.3,4
In patients with cancer, nucleic acids obtained from tumor biopsies
and resections remain the main source for molecular profiling. How-
ever, these procedures are invasive, costly, time-consuming, and have
only limited potential to be repeated in longitudinal studies.5 Their
relevance is further limited by the prevalence of intra-tumor genetic
heterogeneity as shown in multiple sequencing studies over the past
decade.5,6 Thus, a single biopsy of the primary tumor is not likely to be
genetically representative of the whole tumor. To overcome these
challenges, circulating cell-freeDNA (cfDNA) has been proposed as an
alternative because it can be collected less invasively compared with
conventional biopsies.7,8 Circulating cfDNA is a type of cell-free
nucleic acid that derives from apoptotic and necrotic cells or is
released from living eukaryotic cells.9 The detection of DNA in the
blood originating from tumors in patients with cancer has been
described decades ago.10-12 The fraction of cfDNA derived from tumor
is termed circulating tumor DNA (ctDNA).7,8 ctDNA can be
considered a new source for the detection and surveillance of major
cancers because it is more likely to be present in patients with cancer.7,8
The potential of using cfDNA as an indicator of disease burden
with prognostic implication and clinical applicability during follow-
up and monitoring in both the curative and palliative setting has
been investigated in numerous studies.13,14 Cancer-specific
mutations, copy number alterations, and genomic rearrangements
assessed in ctDNA demonstrated potential prognostic and predictive
significance.15-20 To further evaluate prognostic and predictive
biomarkers in cfDNA and assess its value as a disease monitoring
tool, longitudinal studies with long follow-up are necessary. The
utility of the technology depends on its capability to assess
sequential samples that have been collected and stored over a long
period of time. This study aims to assess the feasibility of cfDNA
extraction and somatic mutation assessment in 30-year-old serum
that has been collected from patients with breast cancer between
1983 and 1991.
Materials and Methods
Patients and Serum
For this study, we had access to serum samples from 753 patients
with cancer, which were collected between 1983 and 1991 in an
oncologic private practice in Basel, Switzerland. Of 753 patients,
152 were females with breast cancer. The patients were referred to
the medical oncologist either after surgery of the primary tumor
or after the diagnosis of local/regional recurrence and/or distant
metastases. After obtaining informed consent, 10 mL of nativeClinical Breast Cancer October 2020venous blood were collected in a 10-mL BD Vacutainer blood
collection tube and centrifuged in a Hettich centrifuge at 5000 rpm
for 10 minutes. The serum samples were immediately frozen and
stored at 70C to 80C in 3 Nunc Cryogenic tubes per patient
(Gibko AG) at a private office during the first 9 years; thereafter,
the samples have been transferred to the Institute of Immunobi-
ology in Freiburg, Germany, by using transportable refrigerating
boxes to avoid thawing. In 1999, the samples were relocated to the
Laboratory for Medical Genetics of the University of Basel,
Switzerland, and stored until processing and analysis. Clinico-
pathologic variables regarding patient demographics, primary
tumor, treatment, recurrence, and survival were retrieved from
clinical files. Approval for the use of these samples and correlating
data has been granted by the responsible ethics committee (approval
number: eknz-2018-00252).
cfDNA Extraction
Circulating DNA was extracted from 2 to 4 mL of isolated serum
from 52 randomly selected patients with breast cancer with the
QIAamp Circulating Nucleic Acid Kit (Qiagen) as previously
described.21 DNA was quantified using the Qubit Fluorometer
(Invitrogen) and analyzed using the 2200 TapeStation system
(Agilent Technologies) with the High Sensitivity DNA Analysis Kit.
Targeted Sequencing and Library Preparation
Sequencing was performed using 2 different amplicon-based
targeted sequencing panels. The first 10 randomly selected
samples were sequenced with the Oncomine Breast cfDNA Assay
(A31183, Thermo Fisher Scientific). This panel covers 152 hotspot
mutations in 10 genes (AKT1, EGFR, ERBB2, ERBB3, ESR1,
FBXW7, KRAS, PIK3CA, SF3B1, and TP53) across 26 amplicons.
This integrates the TagSeq technology (molecular barcode) and
allows detection of rare variants present at 0.1% allelic frequency.
Library preparation, molecular barcoding, and sequencing were
performed according to the instructions and guidelines provided by
Thermo Fisher, using 5 ng of DNA as input. Briefly, the library
preparation protocol was based on a 2-step cycle multiplex touch-
down polymerase chain reaction (PCR) with a temperature
ranging from 64 C to 58 C, which allowed to amplify target
regions and to introduce unique molecular identifiers. The obtained
tagged amplicons of around 100 to 140 bp length were then cleaned
up using Agencourt AMPure XP (Beckman Coulter), then eluted in
24 ml low TE buffer. A second round of PCR (18 cycles) was
performed in a total volume of 50 ml to amplify the purified
amplicons and to introduce Ion Torrent Tag-Sequencing adapters
containing sample-specific barcodes. The resulting library of target
DNA fragments was purified by performing a 2-step cleanup using
Agencourt AMPure XP (Beckman Coulter). The purified libraries
were then diluted 1:1000 and quantified by qPCR using the Ion
Universal Quantitation Kit (Thermo Fisher Scientific). The
quantified stock libraries were then diluted to 100 pM for down-
stream template preparation. Subsequentially, sequencing runs were
planned on the Torrent Suite Software v5.2, and libraries were
pooled and loaded on an Ion 540 chip using the Ion Chef
Instrument (Thermo Fisher Scientific). The loaded chip was then
sequenced using 500 flows on an S5 system (Thermo Fisher
Scientific).
Table 1 Clinicopathologic Parameters of 52 Patients With
Breast Cancer
Survival and Recurrences
n (%) or
Median (IQR)
No. patients with clinical data and serum 52
Median age at first diagnosis, y 49.5 (45.5-60.5)
Median follow-up time from diagnosis to death
or last follow-up, y
7.9
(3.7-15.5)
Median time from initial diagnosis to date
of sample collection, y
1.6
(1.0-4.8)
No. breast cancer-specific deaths 32 (62)
No. deaths unrelated to breast cancer 4 (7)
Cause of death unknown 2 (3)
Median overall survival from diagnosis to death, y 6.8 (3.2-13.9)
Median disease-free survival diagnosis to local/regional
or distant recurrence, second breast cancer or death, y
2.7
(1.5-6.4)
Treatment at first diagnosis
Neoadjuvant treatment 2 (3)
Surgery 50 (96)
Adjuvant radiation 18 (35)
Adjuvant tamoxifen 18 (35)
Adjuvant CMF (v p) or LMF (vp)
chemotherapies
15 (28)
Other adjuvant systemic therapies 3 (5)
Clinicopathological parameters at first diagnosis
Female 52 (100)
Laterality
Left 25 (48)
Right 24 (47)
Bilateral 3 (5)
Gradea
1 1 (2)
2 14 (27)
3 37 (71)
Hormone receptor statusa
Positive 42 (82)
Negative 10 (18)
T stage
1 14 (27)
2 28 (54)
3 5 (10)
4 4 (7)
X 1 (2)
N stage
0 16 (31)
1 26 (50)
2 6 (11)
3 1 (2)
X 3 (6)
Table 1 Continued
Survival and Recurrences
n (%) or
Median (IQR)
M stage
0 50 (97)
1 2 (3)
Abbreviations: C ¼ cyclophosphamide; F ¼ fluorouracil; IQR ¼ interquartile range;
L ¼ chlorambucil (leukeran); M ¼ methotrexate; P ¼ prednisone; V ¼ vincristine.
aHad not been assessed routinely at the time.
Mathilde Ritter et alIn a second round, 15 randomly selected samples were
sequenced with a custom targeted sequencing panel focusing on
the most frequently altered genes in breast cancer previously
described.22 Library preparation for the breast panel was per-
formed using the Ion AmpliSeq library kit 2.0 (Thermo Fisher
Scientific) according to the manufacturer’s guidelines. The panel
consists of 2 pools of amplification primers. Ten ng of DNA per
sample were used for library preparation for each pool. Amplifi-
cation was performed according to the manufacturer’s guidelines.
The amplicons from the 2 pools were combined and treated to
digest the primers and to phosphorylate the amplicons. The
amplicons were then ligated to Ion Xpress Barcode Adapters
(Thermo Fisher Scientific) using DNA ligase. Finally, cleaning
and purification of the generated libraries were performed with
Agencourt AMPure XP (Beckman Coulter) according to the
manufacturer’s guidelines. Quantification and quality control
were performed with Ion Library TaqMan Quantitation Kit
(Thermo Fisher Scientific). Samples were diluted to reach the
concentration of 40 pmol and then were pooled for sequencing.
Twenty-five ml of the pooled libraries were loaded on Ion 540
Chip (Thermo Fisher Scientific) and processed in Ion Chef In-
strument (Thermo Fisher Scientific). Sequencing was performed
on Ion S5XL system (Thermo Fisher Scientific).23
Somatic Variants Identification
Raw data were processed automatically on the Torrent Server and
aligned to the reference hg19 genome. The analysis pipeline included
signal processing, base calling, quality score assignment, adapter
trimming, PCR duplicate removal, and control of mapping quality.
All samples passed the quality check and met the requirements of a
minimum molecular average depth. The first round of samples
sequencing data (n ¼ 10) was uploaded in BAM format to the Ion
Reporter Analysis Server for variant calling and annotation. Variant
calling was performed on Ion Reporter (IR) Analysis Software v5.2
using the Oncomine TagSeq Breast Liquid Biopsy w2.0 workflow.
Coverage metrics for each amplicon were obtained by running the
Coverage Analysis Plugin software v5.2.1 (Thermo Fisher Scientific).
Identified variants were only considered if the variant had a molecular
coverage of at least 3, indicating that the variant was detected in 3
independent template molecules. Finally, all candidate mutations
were manually reviewed using the Integrative Genomics Viewer37.Clinical Breast Cancer October 2020 - 415
Table 2 Circulating Free DNA Extraction Data
Sample Name Serum, mL
Concentration,
ng/uL
#001 3 1.5
#002 4 2.5
#003 3.2 9.6
#004 3 0.6
#005 3.5 8.8
#006 3.5 10.3
#007 2.5 12.1
#008 2 1.4
#009 3 3.7
#010 3 3.4
#011 3.5 10
#012 4 10.5
#013 3.2 6.7
#014 2.5 6.5
#015 2.5 5.4
#016 3 3.7
#017 3 1.2
#018 3 0.25
#019 3.5 3.4
#020 3 3.4
#021 3.2 7.5
#022 2 2.5
#023 4 1.1
#024 3 2.5
#025 4 28
#026 3 3.9
#027 3.5 4.9
#028 4 8.1
#029 3 9.1
#030 3 2.9
#031 3 2.3
#032 3.5 1.7
#033 4 2.8
#034 3 1.4
#035 3 5.3
#036 3 2.3
#037 3 0.8
#038 2.5 7.9
#039 3 1.8
#040 3 4.2
#041 4 19.3
#042 3.5 4.2
#043 2.5 9.2
#044 2.5 17.8
#045 2.5 2.4
#046 3.5 2.7
#047 2.5 1.6
#048 4 54
#049 2.5 6.4
#050 3 1.9
#051 3 15.3
#052 2.5 0.7
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416 -In the second round of sequenced samples (n ¼ 15), variant
calling was performed with TVC version 5.0.3 (Torrent Variant
Caller, Thermo Fisher Scientific) using low-stringency parameters
previously described.24,25 Briefly, mutations detected by TVC were
subsequently filtered by the following steps. First, all the multiallelic
variants have been split and left aligned. Moreover, the presence and
the relative length of homopolymer sequences were annotated to
take into account the presence of possible wrongly aligned
sequencing reads and, therefore, false-positive variants. Second,
because the 15 samples had no matched germline samples, all the
variants have been annotated using 3 databases: the 1000 Genomes
Project, the Exome Aggregation Consortium, and the NHLBI GO
Exome Sequencing Project.26,27 All the mutations identified by
TVC that were also present within the databases in significative
frequencies (> 5%) have been flagged as probable germline
mutations. Furthermore, a pool of 16 germline samples collected
from an independent cohort was used to provide an additional list of
likely germline mutations that, together with the ones previously
flagged, have been filtered out from the final output list. To avoid
the removal of clinically relevant information, mutations found in
known cancer driver hotspots have been whitelisted and kept even
when they met the criteria for the aforementioned filtering steps.
Results
cfDNA Extraction From 30-year-old Serum of Sufficient
Quality for Sequencing Analysis
We randomly selected 52 of the 152 patients with breast cancer
(clinicopathologic characteristics of patients are shown in Table 1)
to perform cfDNA extraction (Table 2). cfDNA extraction was
successful in all patients, and cfDNA levels were determined for
each sample with a fluorometric quantitation system. We obtained a
range of concentrations from 0.2 to 54 ng/ul (Table 2). To assess
the serum-derived cfDNA integrity and quality, we performed a
capillary electrophoretic separation using the TapeStation system
(Agilent Technology). Electropherograms were generated for each
sample and the fragment size of the cfDNA measured between 2
markers against fluorescence intensity. The mean of cfDNA
fragment size distribution ranged from 106 to 216 bp (average, 136
bp), with no significant differences in cfDNA fragment size between
all samples (Figure 1). Even though the serum samples showed
contamination with high molecular weight genomic DNA in
comparison to samples extracted from plasma (gDNA) (Figure 1), it
was observed that the amount of cfDNA was more than the gDNA
(Figure 1).
Taken together, cfDNA was successfully extracted from all the
samples with sufficient quality for further sequencing analysis,
suggesting the feasibility of the use of long-storage serum for
molecular analysis.
Targeted Sequencing Showed Breast Cancer-specific
Somatic Mutations in cfDNA
From the 52 extracted cfDNA samples, we randomly selected 25
for subsequent mutation investigation. Sequencing was performed
using 2 different targeted panels. Ten samples were sequenced using
the Oncomine Breast cfDNA Assay, which covers the most
common hotspots in 10 highly mutated genes in breast cancer.Clinical Breast Cancer October 2020
Figure 1 Circulating Free DNA Analysis Using the TapeStation System. Representative Electropherograms of Total Extracted
Circulating Free DNA From 4 Patients Selected for Sequencing (#030, #015, #029, #014)
Mathilde Ritter et alOwing to the molecular barcoding, this panel allows for the
identification of mutations at a very low allelic frequency. We
obtained a mean sequencing depth of 55,612X (ranging from 5227
to 108,393) and identified somatic mutations in 8 of the tested
samples encompassing KRAS, TP53 (Table 3A and Figure 2). The
other 15 samples were instead sequenced with a custom targeted
sequencing panel that covers all exons of 27 protein-coding genes as
well as mutation hotspots in 3 cancer genes and the recurrently
mutated lncRNA genes MALAT1 and NEAT128 (see Supplemental
Table 1 in the online version). In this second round of sequencing,
we obtained a mean sequencing depth of 2891X (ranging from 903
to 18,210), and we identified somatic mutations in 12 of the testedsamples (Table 3B and Figure 2). Mutations were detected in some
of the most commonly mutated genes in breast cancer, as
TP53(p.Arg248Trp) and PTEN(p.Phe278Leu).
Taken together, a total of 24 cancer-specific mutations in 10 of
the most commonly mutated breast cancer genes were found in 22
(88%) of 25 randomly selected 30-year-old serum-derived cfDNA
from patients with breast cancer (Figure 2), suggesting the feasibility
of using very old serum samples for mutational profiles.
Discussion
The present cohort of patients with breast cancer with complete
long-term follow-up and available blood samples taken 30 years agoClinical Breast Cancer October 2020 - 417
Table 3 Depth of Sequencing
A, Sequencing with Oncomine Breast Circulating Free DNA Assay
Sample Name Mapped Reads On Target Mean Coverage KRAS TP53 PIK3CA
#012 822,290 95.84 32,400 p.G12D (0.1%)
#017 1,513,454 96.98 60,944 p.R248W (0.1%) p.H1047R (2.84%)
#026 1,430,359 95.98 56,798
#028 17,27,543 97.76 73,289 p.R158L (1.58%)
#031 1,719,712 96.01 69,907 p.G12C (0.1%)
#033 978,141 96.31 39,142 p.R248W (0.1%)
#035 1,084,084 95.86 43,583
#039 135,999 97.44 5227 p.V173M (0.46%)
#041 1,626,548 96.08 66,433 p.G154V (0.06%)
#051 2,656,056 96.21 108,393 p.H179R (0.14%)
B, Sequencing With Custom Ampliseq Ion Torrent Panel
Sample
Mapped
Reads
On
Target
Mean
Coverage PTEN TP53 AKT1 FOXA1 ARID1B NCOR1 ERBB2 KMT2C
#001 1,695,052 91.83 904 p.Phe2313Ser (0.51)
#002 33,435,937 92.57 18,210 p.Val272Leu (0.08) p.Glu17Lys (0.13) p.Cys258Arg (0.4)
#003 3,398,689 93.08 1879 p.Thr766Ala (0.51)
#004 3,357,088 92.24 1729
#005 3,924,417 92.69 2151 p.Phe278Leu (0.25)
#010 3,138,700 93.12 1589 c.993þ1G>T (0.56) p.Ser1861Arg (0.16)
#014 2,284,741 93.62 1265 p.Lys230Gln (0.16)
#015 6,629,734 94.07 3529 p.Pro1170fs (0.1)
#019 4,542,595 93.35 2516 p.Gln124_Gln131del (0.07
#022 2,169,116 93.45 1160 p.Lys230Gln (0.13)
#029 3,605,091 93.79 1975 p.Gln128_Gln129dup (0.2
#030 3,090,414 94.6 1606 p.Lys2336Asn (0.48)
#032 3,743,126 91.21 2031
#037 2,094,065 91.87 1093 p.Phe278Leu (0.27)
#052 3,098,154 93.8 1689
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Figure 2 Heatmap of the Comparison of all the Somatic Mutations Found in 25 Randomly Selected Samples Across the Whole Cohort.
Rows Indicate the Specific Samples, Columns Indicate the Specific Mutations, Annotated With the Gene Name and the
Specific Aminoacidic Change. The Heatmap Shows the Presence (Blue Cells) or the Lack (Grey Cells) of Mutations
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420 -represents an exceptional opportunity to study the potential of
liquid biopsy-based biomarker identification. The patients were
treated in curative or palliative intent for stage I to IV breast cancer.
Treatment heterogeneity was limited at that time because only
tamoxifen and CMF or LMF (cyclophosphamide- or chlorambucil-
methotrexate-fluorouracil) chemotherapy were used in most
patients who received systemic treatment. The majority of the
patient population recurred at some point, which was the reason
why 35 (62%) of the 52 patients died from breast cancer in this
cohort. The collection of serum started in 1983, whereas the dates
of first diagnosis and treatment go back to 1967. cfDNA was
obtained in sufficient quantity and quality for sequencing in all 52
patients. The sample size was too small to make any firm conclu-
sions on differences between patients with short and long-term
survival. However, the present results suggest that this modern
technology can be used to accurately extract and sequence ctDNA
to detect cancer-specific mutations in these old samples, despite the
long cryopreservation and repeated changes of storage location.
These findings support the use of long-term storage of biological
samples in longitudinal studies prior to analysis, which, in turn, will
increase feasibility by making the study protocols less depending on
consecutive and timely processing at the centralized high-depth tar-
geted sequencing unit. The principle of long-term storage may
facilitate the performance of large international studies that assess the
prognostic role of cancer-associated pathogenic mutations in serum
cfDNA present at diagnosis by comparing overall and relapse-free
survival between patients with or without specific mutations.
Therefore, another potential value of using samples of patients
diagnosed a long time ago is to increase the number of events (eg,
relapse, deaths) and increase the statistical power for survival analyses
(study of the prognostic value of the identified mutations in ctDNA).
The predictive power of response-associated mutations can then be
assessed based on in silico mutation effect predictors and curated
databases of cancer- and response-associated variants.29-35 One would
hypothesize that patients with detectable mutations in the cfDNA
would have higher tumor burden and/or tumor cells with a higher
tendency to shed into the bloodstream and, therefore, poorer
outcome than patients without detectable mutations in the cfDNA.
Candidate somatic mutations can be further evaluated in vitro and
in vivo by using xenograft models. For instance, patient-derived breast
tumor cells can be engineered to express the same mutation found to
be associated with resistance and test their sensitivity to the same
targeted therapy in xenograft models compared with control cancer
cells (ie, wild-type in the corresponding allele).
The blood samples analyzed here were taken at a time when
physicians could not anticipate NGS approaches. Nevertheless,
substantial efforts were made to collect the samples under the
assumption that someday technology would have advanced to the
point where relevant research could be performed with a few mL of
serum and matched clinical data. Storing blood samples over the
entire duration of longitudinal studies allows newly developed
technology to analyze cfDNA more thoroughly and homogenously.
Hence, the most modern state-of-the-art technology for nucleic
acids extraction, sequencing, data analysis, and new targeted panels
that may only become available at the end of the study can be
applied to all serial blood samples, which increases data quality and
comparability. Innovative studies can be designed to track theClinical Breast Cancer October 2020evolution of disease-associated mutations in the serum cfDNA. This
would allow to evaluate if variations in the tumor allele fractions of
the mutations mirror the genetic heterogeneity in the tumors and to
determine if disease progression is associated with the emergence of
additional somatic mutations. This, in turn, may help to assess
whether mutational evolution reflects radiologically determined
disease burden, recurrence, or metastasis.
This study has several limitations. First, some of the mutations
may have been germline variants, especially those at high allelic
frequencies. We cannot exclude this possibility owing to the lack of
germline controls or clonal hematopoiesis. However, the primary
aim of the study was to determine whether it was possible to identify
mutations in 30-year-old serum, and the exclusion of germline
variants can be achieved by using germline control. Second, the
custom panel we used in this study was not optimized for mutation
detection in cfDNA, because some of the amplicons are bigger than
the average size of cfDNA fragments. We may thus have missed
some mutations, and the use of a panel with smaller amplicon size
will likely increase the number of mutations that can be detected.
Third, another important limitation is the small sample size that
precluded any analyses on associations between mutations and
clinical endpoints. For example, it would be interesting to see if
patients with detectable mutations in the cfDNA have a higher
tumor stage and therefore poorer outcome than patients without
detectable mutations. This has been shown in patients with late-
stage gastric cancer, where patients with detectable mutations had
a 5.6% 5-year overall survival rate compared with 31.5% in patients
without detectable mutations.36 TP53 is one of the most frequently
mutated genes in breast cancer, and, being a tumor suppressor and
usually associated with the loss of the wild-type allele, TP53
mutations are likely to be more readily detectable in cfDNA than
activating oncogenic mutations. In fact, 7 of 24 detected mutations
in this series were TP53 mutations. However, it would be very
challenging to adjust for the selection bias in this series of high-risk
patients referred to the medical oncologist for systemic treatment
even if a higher sample size could have been achieved. Nevertheless,
evaluating associations between mutations and clinical endpoints is
an area of high potential relevance, particularly when DNA from
matched archival tissue of primary tumors or distant metastases are
available. As outlook for future projects, we plan to assess the
prognostic role of cancer-associated mutations in the serum cfDNA
at diagnosis with the extensive follow-up information and clinico-
pathologic parameters available for our unique cohort of patients.
In conclusion, the present study shows that current NGS tech-
nology is sufficiently robust and specific to analyze 30-year-old serum.
Based on this finding, longitudinal studies can be designed to bemore
feasible and flexible by storing biological samples over a long period of
time. This allows for uniform sequencing with the most modern
technology and adequate statistical power by cumulating oncologic
events. Our study supports the value of liquid biopsies in assessing the
dynamic changes of genetic heterogeneity over time and in the vali-
dation of new cfDNA biomarkers for breast cancer.
Clinical Practice Points
 The potential of using cfDNA as an indicator of disease burden
with prognostic implication and clinical applicability during
follow-up and monitoring in both the curative and palliative
Mathilde Ritter et alsetting has been investigated in numerous studies. Cancer-
specific mutations, copy number alterations, and genomic
rearrangements assessed in ctDNA demonstrated potential
prognostic and predictive significance.
 To further evaluate prognostic and predictive biomarkers in
cfDNA and assess its value as a disease monitoring tool,
longitudinal studies with long follow-up are necessary. The
utility of the technology depends on its capability to assess
sequential samples that have been collected and stored over a
long period of time.
 The aim of this study was to assess the feasibility of cfDNA
extraction and somatic mutation assessment in 30-year-old
serum. We evaluated samples from 52 patients with breast
cancer, which were collected between 1983 and 1991. cfDNA
extraction was successful in 52 of 52 patients, and 24 cancer-
specific mutations were found in 22 of 25 samples undergoing
sequencing.
 Our results suggest that current NGS technology is sufficiently
robust and specific to analyze 30-year-old serum. Based on this
finding, longitudinal studies can be designed to be more feasible
and flexible by storing biological samples over a long period of
time. This allows for uniform sequencing with the most modern
technology and adequate statistical power by cumulating
oncologic events. Our study supports the value of liquid biopsies
in assessing the dynamic changes of genetic heterogeneity over
time and in the validation of new cfDNA biomarkers for breast
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421.eSupplemental DataSupplemental Table 1 Gene Coverage of the Custom Targeted Sequencing Panel
Gene Name Chromosome Start End Cytoband Remarks
ARID1A 1 27022524 27108595 p36.11 Complete coding region
NRAS 1 115247090 115259515 p13.2 Hotspot residues 12,13 and 61 only
SETD2 3 47057919 47205457 p21.31 Complete coding region
PIK3CA 3 178865902 178957881 q26.32 Complete coding region
FBXW7 4 153242410 153457253 q31.3 Complete coding region
MAP3K1 5 56111401 56191979 q11.2 Complete coding region
PIK3R1 5 67511548 67597649 q13.1 Complete coding region
ARID1B 6 157099063 157531913 q25.3 Complete coding region
EGFR 7 55086714 55324313 p11.2 Complete coding region
KMT2C 7 151832010 152133090 q36.1 Complete coding region
PTPRD 9 8314246 10612723 p23 Complete coding region
GAT A3 10 8095567 8117161 p14 Complete coding region
PTEN 10 89622870 89731687 q23.31 Complete coding region
HRAS 11 532242 537287 p15.5 Hotspot residues 12, 13, and 61 only
NEAT1 11 65190245 65213011 q13.1 Complete coding region
MALAT1 11 65265233 65273940 q13.1 Complete coding region
ATM 11 108093211 108239829 q22.3 Complete coding region
KRAS 12 25357723 25403870 p12.1 Hotspot residues 12, 13, and 61 only
ERBB3 12 56473641 56497289 q13.2 Complete coding region
TBX3 12 115108059 115121969 q24.21 Complete coding region
RBI 13 48877887 49056122 q14.2 Complete coding region
F0XA1 14 38059189 38069245 q21.1 Complete coding region
AKT1 14 105235686 105262088 q32.33 Complete coding region
CBFB 16 67063019 67134961 q22.1 Complete coding region
CTCF 16 67596310 67673086 q22.1 Complete coding region
CDH1 16 68771128 68869451 q22.1 Complete coding region
TP53 17 7565097 7590856 p13.1 Complete coding region
MAP2K4 17 11924141 12047147 P12 Complete coding region
NCOR1 17 15932471 16121499 p11.2 Complete coding region
NF1 17 29421945 29709134 q11.2 Complete coding region
ERBB2 17 37844167 37886679 q12 Complete coding region
RUNX1 21 36160098 37376965 q22.12 Complete coding region
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